{"symbol":"REGN","fiscalQuarter":"Q4-2019","reportDate":"2020-02-06","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2019","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.75%","keyNumbers":[{"metric":"EPS","actual":"$7.50","expected":"N/A","surprise":"+6.92%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They noted ongoing investments in research and development.","There was an emphasis on maintaining a robust pipeline for future growth."],"summary":"Management expressed confidence in the company's current trajectory and product pipeline. They are focused on long-term growth despite not providing specific guidance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and possibly strong sales in their key products. The stock's 4.75% increase reflects investor confidence in the company's future potential. However, the lack of revenue data and guidance leaves some uncertainty about the overall financial outlook.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2019 earnings: EPS beat by 6.92%. Stock up 4.75%. Full breakdown."}}